The effect of levocarnitine supplementation on dialysis-related hypotension: A systematic review, meta-analysis, and trial sequential analysis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
10
03
2022
accepted:
27
06
2022
entrez:
14
7
2022
pubmed:
15
7
2022
medline:
19
7
2022
Statut:
epublish
Résumé
Dialysis patients have been shown to have low serum carnitine due to poor nutrition, deprivation of endogenous synthesis from kidneys, and removal by hemodialysis. Carnitine deficiency leads to impaired cardiac function and dialysis-related hypotension which are associated with increased mortality. Supplementing with levocarnitine among hemodialysis patients may diminish incidence of intradialytic hypotension. Data on this topic, however, lacks consensus. We conducted electronic searches in PubMed, Embase and Cochrane Central Register of Controlled Trials from January 1960 to 19th November 2021 to identify randomized controlled studies (RCTs), which examined the effects of oral or intravenous levocarnitine (L-carnitine) on dialysis-related hypotension among hemodialysis patients. The secondary outcome was muscle cramps. Study results were pooled and analyzed utilizing the random-effects model. Trial sequential analysis (TSA) was performed to assess the strength of current evidence. Eight trials with 224 participants were included in our meta-analysis. Compared to control group, L-carnitine reduced the incidence of dialysis-related hypotension among hemodialysis patients (pooled OR = 0.26, 95% CI [0.10-0.72], p = 0.01, I2 = 76.0%). TSA demonstrated that the evidence was sufficient to conclude the finding. Five studies with 147 participants showed a reduction in the incidence of muscle cramps with L-carnitine group (pooled OR = 0.22, 95% CI [0.06-0.81], p = 0.02, I2 = 74.7%). However, TSA suggested that further high-quality studies were required. Subgroup analysis on the route of supplementation revealed that only oral but not intravenous L-carnitine significantly reduced dialysis-related hypotension. Regarding dose and duration of L-carnitine supplementation, the dose > 4,200 mg/week and duration of at least 12 weeks appeared to prevent dialysis-related hypotension. Supplementing oral L-carnitine for at least three months above 4,200 mg/week helps prevent dialysis-related hypotension. L-carnitine supplementation may ameliorate muscle cramps. Further well-powered studies are required to conclude this benefit.
Sections du résumé
BACKGROUND
Dialysis patients have been shown to have low serum carnitine due to poor nutrition, deprivation of endogenous synthesis from kidneys, and removal by hemodialysis. Carnitine deficiency leads to impaired cardiac function and dialysis-related hypotension which are associated with increased mortality. Supplementing with levocarnitine among hemodialysis patients may diminish incidence of intradialytic hypotension. Data on this topic, however, lacks consensus.
METHODS
We conducted electronic searches in PubMed, Embase and Cochrane Central Register of Controlled Trials from January 1960 to 19th November 2021 to identify randomized controlled studies (RCTs), which examined the effects of oral or intravenous levocarnitine (L-carnitine) on dialysis-related hypotension among hemodialysis patients. The secondary outcome was muscle cramps. Study results were pooled and analyzed utilizing the random-effects model. Trial sequential analysis (TSA) was performed to assess the strength of current evidence.
RESULTS
Eight trials with 224 participants were included in our meta-analysis. Compared to control group, L-carnitine reduced the incidence of dialysis-related hypotension among hemodialysis patients (pooled OR = 0.26, 95% CI [0.10-0.72], p = 0.01, I2 = 76.0%). TSA demonstrated that the evidence was sufficient to conclude the finding. Five studies with 147 participants showed a reduction in the incidence of muscle cramps with L-carnitine group (pooled OR = 0.22, 95% CI [0.06-0.81], p = 0.02, I2 = 74.7%). However, TSA suggested that further high-quality studies were required. Subgroup analysis on the route of supplementation revealed that only oral but not intravenous L-carnitine significantly reduced dialysis-related hypotension. Regarding dose and duration of L-carnitine supplementation, the dose > 4,200 mg/week and duration of at least 12 weeks appeared to prevent dialysis-related hypotension.
CONCLUSION
Supplementing oral L-carnitine for at least three months above 4,200 mg/week helps prevent dialysis-related hypotension. L-carnitine supplementation may ameliorate muscle cramps. Further well-powered studies are required to conclude this benefit.
Identifiants
pubmed: 35834513
doi: 10.1371/journal.pone.0271307
pii: PONE-D-22-07106
pmc: PMC9282471
doi:
Substances chimiques
Carnitine
S7UI8SM58A
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0271307Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Pharmacol Res. 2011 Mar;63(3):157-64
pubmed: 21138768
J Am Soc Nephrol. 1993 Nov;4(5):1178-83
pubmed: 8305644
Kidney Int. 1990 Nov;38(5):912-8
pubmed: 2266675
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Am J Kidney Dis. 2016 Feb;67(2):260-70
pubmed: 26508680
Kidney Int. 2004 Sep;66(3):1212-20
pubmed: 15327420
Nutr Clin Pract. 2005 Apr;20(2):218-43
pubmed: 16207659
Am J Physiol. 1985 Mar;248(3 Pt 1):G313-9
pubmed: 3976890
Contrib Nephrol. 1992;98:28-35
pubmed: 1493731
Scand J Clin Lab Invest. 1985 May;45(3):193-8
pubmed: 3890132
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
BMC Med Res Methodol. 2020 Nov 30;20(1):284
pubmed: 33256626
Kidney Int. 1992 Jun;41(6):1613-9
pubmed: 1501417
Kidney Int Rep. 2020 Mar 12;5(6):924-926
pubmed: 32518876
Jpn Circ J. 1983 Dec;47(12):1391-7
pubmed: 6228676
Nephrourol Mon. 2013 Sep;5(4):862-5
pubmed: 24350082
Annu Rev Pharmacol Toxicol. 1987;27:257-77
pubmed: 3555318
Nihon Jinzo Gakkai Shi. 1984 Feb;26(2):195-202
pubmed: 6748336
Indian J Med Sci. 2006 Apr;60(4):143-53
pubmed: 16679630
Clin Nephrol. 2000 Dec;54(6):470-7
pubmed: 11140808
Clin Ther. 1995 Mar-Apr;17(2):176-85; discussion 175
pubmed: 7614519
Cardiorenal Med. 2013 Oct;3(3):200-207
pubmed: 24454315
Intern Med. 2018 Dec 15;57(24):3503-3505
pubmed: 30146610
Curr Med Res Opin. 2002;18(3):172-5
pubmed: 12094827
Ther Apher Dial. 2017 Oct;21(5):459-464
pubmed: 28805348
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Clin Pharmacokinet. 2012 Sep 1;51(9):553-72
pubmed: 22804748
Am J Kidney Dis. 2003 Apr;41(4 Suppl 4):S35-43
pubmed: 12751052
Am J Nephrol. 2013;38(5):388-96
pubmed: 24192428
Nihon Jinzo Gakkai Shi. 1983 Apr;25(4):429-38
pubmed: 6620695
Nephrol Dial Transplant. 2003 Dec;18(12):2601-5
pubmed: 14605284
Nutrients. 2021 Apr 07;13(4):
pubmed: 33917145
J Clin Epidemiol. 2017 Apr;84:105-113
pubmed: 28257927
Lancet. 1991 Apr 13;337(8746):867-72
pubmed: 1672966
Nephron Clin Pract. 2004;97(2):c41-8
pubmed: 15218329
J Am Soc Nephrol. 2008 Jan;19(1):8-11
pubmed: 18178796
Nephrol Dial Transplant. 2007 May;22 Suppl 2:ii22-44
pubmed: 17507425
Blood Purif. 2020;49(1-2):158-167
pubmed: 31851975
J Ren Nutr. 2003 Jan;13(1):2-14
pubmed: 12563618
Kidney Int. 2016 May;89(5):1144-1152
pubmed: 27083288
Am J Kidney Dis. 2008 Nov;52(5):962-71
pubmed: 18706751
Nat Med. 2013 May;19(5):576-85
pubmed: 23563705
Contrib Nephrol. 2018;196:96-100
pubmed: 30041211
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120